Wordt geladen...
Association of Coprescription of Triptan Antimigraine Drugs and Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor Antidepressants With Serotonin Syndrome
IMPORTANCE: In 2006, the US Food and Drug Administration (FDA) issued an advisory warning on the risk of serotonin syndrome with concomitant use of triptans and selective serotonin reuptake inhibitor (SSRI) or selective norepinephrine reuptake inhibitor (SNRI) antidepressants, but the true risk of s...
Bewaard in:
| Gepubliceerd in: | JAMA Neurol |
|---|---|
| Hoofdauteurs: | , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
American Medical Association
2018
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5885255/ https://ncbi.nlm.nih.gov/pubmed/29482205 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaneurol.2017.5144 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|